ABILIFY: payments to doctors
Payments that named ABILIFY as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
Was your doctor paid by E.r. Squibb & Sons, L.L.C.?
E.r. Squibb & Sons, L.L.C. reported the most payments naming ABILIFY. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $23K
- Providers
- 486
- Transactions
- 552
- Average per transaction
- $42
The per-transaction average — $42 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 486 providers the average total is $48, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | $11,230 | 48.6% |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $11,004 | 47.7% |
| Bristol Myers Squibb | $350 | 1.5% |
| Otsuka Pharmaceutical Co., Ltd. | $265 | 1.1% |
| Otsuka America Pharmaceutical, Inc. | $238 | 1.0% |
Other products from E.r. Squibb & Sons, L.L.C.
The company that reported the most payments naming ABILIFY also reports against these.